| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000003683 |
| Receipt No. | R000004463 |
| Official scientific title of the study | The efficacy of ferulic acid in the treatment of dementia |
| Date of disclosure of the study information | 2010/05/31 |
| Last modified on | 2016/04/28 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | The efficacy of ferulic acid in the treatment of dementia | |
| Title of the study (Brief title) | EFATD | |
| Region |
|
|
| Condition | ||
| Condition | Alzheimer's Disease, Dementia of Lewy Body,Vascular Dementia, Frontotemporal Dementia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy of ferulic acid in the treatment of dementia |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Hasegawa Dementia Rating Scale,
Mini Mental State Examination, Electroencephalography, MRI,NPI(Neuropsychiatric Inventory),NPI-D(Neuropsychiatric Inventory Caregiver Distress Scale),Trail Making Test |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Taking of Ferulic Acid for 6 months followed by Not taking of Ferulic Acid for 6 months.
|
|
| Interventions/Control_2 | Not taking of Ferulic Acid for 6 months followed by taking of Ferulic Acid for 6 months.
|
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Due to side effects dementia
patients who can not take donepezil. |
|||
| Key exclusion criteria | head trauma,malignancy,metabolic encephalopathy,alcohl abuse, Mental disorder,chronic renal failure and patients treated by major tranquilizer. | |||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroaki Oguro |
| Organization | Shimane University Hospital |
| Division name | Department of Neurology |
| Address | Izumo city,Enya 89-1 |
| TEL | 0853202198 |
| oguro@med.shimane-u.ac.jp | |
| Public contact | |
| Name of contact person | Hiroaki Oguro |
| Organization | Shimane University Hospital |
| Division name | Department of Neurology |
| Address | Izumo city |
| TEL | 0853202198 |
| Homepage URL | |
| oguro@med.shimane-u.ac.jp | |
| Sponsor | |
| Institute | Shimane University Hospital |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | GLOVIA |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 島根大学医学部附属病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004463 |